

Special Issue

Nanotechnology in Pharmaceuticals

Message from the Guest Editors

The introduction of nanotechnology into pharmaceutical sciences has revolutionized therapeutic outcomes. Nanotechnology in pharmaceuticals has evolved significantly with the development of diverse nanocarriers, including micelles, lipid nanoparticles, inorganic nanoparticles, polymeric nanoparticles, protein-based nanoparticles, polymer–lipid hybrid nanoparticles, polymer–drug conjugates, lipid–drug conjugates, protein– and peptide–drug conjugates, and polymersomes.

Nanotechnology has been widely adopted in treating infectious, chronic, genetic, degenerative, and autoimmune diseases, as well as cancer. With the remarkable impact of nanotechnology in pharmaceuticals, this Special Issue aims to highlight the wide applicability of nanotechnology in various aspects of therapeutics, diagnostics, and theranostics, encompassing numerous routes of administration, which include oral, intravenous, intramuscular, subcutaneous, ocular, pulmonary, topical, and intranasal. Hence, we invite reviews and research articles focusing on nanotechnology in various aspects of pharmaceuticals.

Guest Editors

Dr. Pratap Basim

Thermo Fisher Scientific, Cincinnati, OH 45237, USA

Dr. Geetha Vaskuri

Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA

Dr. Nagavendra Kommineni

Thermo Fisher Scientific, Cincinnati, OH 45237, USA

Deadline for manuscript submissions

31 August 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/245256

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).